AstraZeneca FY2026 EPS Estimate Increased by Leerink Partnrs

AstraZeneca PLC (NASDAQ:AZN - Free Report) - Equities researchers at Leerink Partnrs raised their FY2026 earnings estimates for shares of AstraZeneca in a note issued to investors on Monday, July 14th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of $5.12 per share for the year, up from their prior estimate of $5.11. The consensus estimate for AstraZeneca's current full-year earnings is $4.51 per share.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. The company had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The firm's quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.06 EPS.

A number of other brokerages have also recently issued reports on AZN. BNP Paribas started coverage on AstraZeneca in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price objective on the stock. Berenberg Bank set a $97.00 price objective on AstraZeneca in a research note on Wednesday, July 9th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $89.00.

AstraZeneca Stock Performance

AstraZeneca stock traded down $0.47 during midday trading on Thursday, reaching $68.79. The stock had a trading volume of 2,991,789 shares, compared to its average volume of 5,268,368. AstraZeneca has a 12 month low of $61.24 and a 12 month high of $87.68. The firm's 50-day moving average price is $70.75 and its 200 day moving average price is $70.90. The firm has a market capitalization of $213.34 billion, a PE ratio of 27.63, a P/E/G ratio of 1.29 and a beta of 0.37. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65.

Institutional Investors Weigh In On AstraZeneca

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Banque Transatlantique SA bought a new stake in shares of AstraZeneca during the fourth quarter valued at about $26,000. Confluence Investment Management LLC bought a new stake in shares of AstraZeneca during the first quarter valued at about $27,000. Larson Financial Group LLC increased its position in shares of AstraZeneca by 297.9% during the first quarter. Larson Financial Group LLC now owns 386 shares of the company's stock valued at $28,000 after buying an additional 289 shares during the period. Mascagni Wealth Management Inc. bought a new stake in shares of AstraZeneca during the fourth quarter valued at about $29,000. Finally, FNY Investment Advisers LLC bought a new stake in shares of AstraZeneca during the first quarter valued at about $29,000. 20.35% of the stock is currently owned by institutional investors.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.